In the latest clinical wearables acquisition deal by a medical device company, Medtronic (NYSE: MDT) is in talks to acquire Corventis, a wearables technology maker with a focus on cardiovascular devices. Its products are designed for the early detection and treatment of heart problems. The deal was reported by MobiHealthNews.
It reflects a broader trend of medical device companies working with hospitals to deliver technology that can lower costs, increase patient safety and reduce hospital re-admissions.
Medtronic is looking to acquire Corventis for more than $150 million, according to MobiHealth
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Corventis has two cardiac wearable devices — both cleared by the U.S. Food and Drug Administration. NUVANT Mobile Cardiac Telemetry System detects nonlethal arrhythmias, including atrial fibrillation. It’s water-resistant and collects data continuously. It transmits that data to a wireless receiver worn with a clip or belt.
Another, AVIVO Mobile Patient Management System, is a noninvasive, wireless solution to evaluate physiological changes and monitor signs of cardiac irregularities in patients away from the hospital.
Medtronic declined to comment and Corventis did not respond to a request for comment before this post was published.
Earlier this month Covidien told MedCity News it acquired Zephyr Technology Corp. The ZephyrLIFE platform is designed for remote patient monitoring to reduce hospitalization costs, particularly to prevent falls and bed sores and improve sepsis detection. The technology is also being tested to monitor congestive heart failure patients.
